Australia's Chimeric Therapeutics rises on agreement with MD Anderson

Chimeric Therapeutics

13/09/2023 01:43

** Shares of Chimeric Therapeutics  CHM.AX  rise as much as
10% to A$0.03
    ** Co announces agreement with MD Anderson for Phase 1B CHM
0201 AML study
    ** Says ADVENT-AML will be the first trial to evaluate the
synergy of NK cell therapy in combination with the current
standard of care of Azacitidine with Venetoclax 
    ** It will also be the first trial to evaluate cellular
therapy in newly diagnosed AML patients - co 
    ** CHM stock down 62.5% this year, as of last close 

      


 (Reporting by Aishwarya Nair in Bengaluru)